Ryoyo Ikebuchi Selected Research

Deltaretrovirus Infections (BLV Infection)

1/2018	Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection.
2/2015	Increased expression of the regulatory T cell-associated marker CTLA-4 in bovine leukemia virus infection.
7/2013	Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro.
1/2013	Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus.
5/2012	Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection.
9/2011	Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryoyo Ikebuchi Research Topics

Disease

6	Deltaretrovirus Infections (BLV Infection) 01/2018 - 09/2011
4	Neoplasms (Cancer) 05/2021 - 01/2014
4	Disease Progression 01/2017 - 05/2012
4	Infections 01/2017 - 05/2012
4	Persistent Infection 01/2017 - 09/2011
2	Paratuberculosis (Johne's Disease) 01/2018 - 01/2016
2	Melanoma (Melanoma, Malignant) 01/2017 - 01/2016
2	Lymphoma (Lymphomas) 08/2014 - 05/2010
1	Contact Dermatitis (Eczema, Contact) 01/2019
1	Chronic Disease (Chronic Diseases) 01/2017
1	Sarcoma (Soft Tissue Sarcoma) 01/2017
1	Lymphocytosis 03/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Cattle Diseases (Bovine Diseases) 07/2014
1	Disease Resistance 08/2012

Drug/Important Bio-Agent (IBA)

8	LigandsIBA 01/2018 - 09/2011
3	Proteins (Proteins, Gene)FDA Link 05/2021 - 03/2016
3	AntibodiesIBA 01/2018 - 01/2016
3	B7-H1 AntigenIBA 01/2017 - 09/2011
3	Messenger RNA (mRNA)IBA 02/2015 - 05/2010
2	Blocking AntibodiesIBA 01/2018 - 01/2017
2	CytokinesIBA 03/2016 - 08/2012
2	AntigensIBA 01/2016 - 01/2014
1	LipopolysaccharidesIBA 05/2021
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2018
1	Interferon-gamma (Interferon, gamma)IBA 01/2018
1	Dinoprostone (PGE2)FDA Link 01/2018
1	Tuberculin (PPD)IBA 01/2018
1	Immune Checkpoint ProteinsIBA 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	VaccinesIBA 06/2016
1	PerforinIBA 03/2016
1	Immune Checkpoint InhibitorsIBA 01/2016
1	Immunoglobulin M (IgM)IBA 08/2014
1	Histocompatibility Antigens Class IIIBA 01/2013
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2012
1	MucinsIBA 05/2012

Therapy/Procedure

4	Immunotherapy 01/2017 - 09/2011
4	Therapeutics 06/2016 - 07/2013